Bristol Myers Squibb Announces Dividend Increase and Additional $15 Billion Share Repurchase Authorization Pharmaceutical Investing
Yescarta® Demonstrates Durable Two-Year Clinical Benefit in Adults With Relapsed or Refractory Indolent Non-Hodgkin Lymphoma Including Follicular Lymphoma Pharmaceutical Investing
Yescarta® Is First CAR T-cell Therapy to Report Five-Year Survival Data From Pivotal Study Showing Durable Long-Term Survival in Patients With Refractory Large B-cell Lymphoma Pharmaceutical Investing
Yescarta® CAR T-Cell Therapy Quadruples Median Event-Free Survival Duration Over Standard of Care in Second-Line Relapsed or Refractory Large B-Cell Lymphoma Pharmaceutical Investing
Bristol Myers Squibb's Breyanzi Significantly Improves Outcomes, Showing Superiority Over 20-Year Standard of Care in Second-Line Relapsed or Refractory Large B-cell Lymphoma Based on TRANSFORM Study Results Pharmaceutical Investing
Trodelvy® Demonstrates Clinical Benefit for Black Patients Consistent with Full Metastatic Triple-Negative Breast Cancer Population in ASCENT Study Pharmaceutical Investing
VUITY 1.25%, the First and Only FDA-Approved Eye Drop to Treat Age-Related Blurry Near Vision , is Now Available Pharmaceutical Investing
BriaCell Summarizes Clinical Data Poster Presented at the 2021 San Antonio Breast Cancer Symposium® Life Science Investing
Aurinia Announces Positive Topline Results From the AURORA 2 Continuation Study of LUPKYNIS for the Treatment of Adults With Active Lupus Nephritis Pharmaceutical Investing
Lexaria's DehydraTECH-CBD Reduces Arterial Stiffness, Results Confirmed in Human Clinical Study HYPER-H21-2 Company News
Lexaria's DehydraTECHTM-CBD Reduces Arterial Stiffness, Results Confirmed in Human Clinical Study HYPER-H21-2 Company News
BioHarvest Sciences Inc. Produces Significant Amount of Cannabis Without Growing the Cannabis Plant Cannabis Investing News
